Abstract:Mumps virus is highly neurotropic, with evidence of infection of the central nervous system in more than half of clinical cases. In the prevaccine era, mumps was a major cause of viral meningitis in most developed countries. Despite efforts to attenuate the virus, some mumps vaccines have retained virulence properties and have caused aseptic meningitis in vaccinees, resulting in public resistance to vaccination in some countries. Ensuring the safety of mumps vaccines is an important public health objective, as the need for robust immunization programs has been made clear by the recent resurgence of mumps outbreaks worldwide, including the United States, which in 2006 experienced its largest mumps outbreak in 20 years. To better understand the molecular basis of mumps virus attenuation, the authors developed two infectious full-length cDNA clones for a highly neurovirulent strain of mumps virus. The clones differed at only one site, possessing either an A or G at nucleotide position 271 in the F gene, to represent the heterogeneity identified in the original virulent clinical isolate. In comparison to the clinical isolate, virus rescued from the A-variant cDNA clone grew to higher cumulative titers in vitro but exhibited similar cytopathic effects in vitro and virulence in vivo. In contrast, virus rescued from the G-variant cDNA clone, in comparison to the clinical isolate and the A-variant, was more fusogenic in vitro but replicated to lower cumulative titers and was less neurovirulent in vivo. These data suggest that nucleotide position 271 in the F gene plays a significant role in virus pathogenesis. This infectious clone system will serve as a key tool for further examination of the molecular basis for mumps virus neurovirulence and neuroattenuation.

The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study

Neurovirulence safety testing of mumps vaccines--historical perspective and current status

Establishment of a model to assess mumps virus neurovirulence in neonatal Wistar rats

Gene-specific contributions to mumps virus neurovirulence and neuroattenuation

[Comparative evaluation of Leningrad-3 mumps vaccine virus neurovirulence in a neonatal rat model]

Establishment of an Efficient Reverse Genetic System of Mumps Virus S79 from Cloned DNA

Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype

The F gene of rodent brain-adapted mumps virus is a major determinant of neurovirulence

Development of Improved Mumps Vaccine Candidates by Mutating Viral mRNA Cap Methyltransferase Sites in the Large Polymerase Protein

The role of non-human primates in the neurological safety of live viral vaccines (review)

Immunogenicity of novel mumps vaccine candidates generated by genetic modification

Infection of mice, ferrets, and rhesus macaques with a clinical mumps virus isolate

Neurovirulence of mumps virus: intraspinal inoculation test in marmosets

Changes in mumps virus neurovirulence phenotype associated with quasispecies heterogeneity

Identification of genetic mutations associated with attenuation and changes in tropism of Urabe mumps virus

Functional consequences of attenuating mutations in the haemagglutinin neuraminidase, fusion and polymerase proteins of a wild-type mumps virus strain

Establishing a small animal model for evaluating protective immunity against mumps virus

Influence of population diversity on neurovirulence potential of plaque purified L-Zagreb variants

A single nucleotide change in the mumps virus F gene affects virus fusogenicity in vitro and virulence in vivo

Potent neutralizing human monoclonal antibodies protect from Rift Valley fever encephalitis

Factors influencing preclinical in vivo evaluation of mumps vaccine strain immunogenicity